Dr. Kenneth Wright engineers therapeutic peptides for cardiovascular applications at Caltech. His laboratory specializes in rational protein engineering, half-life extension strategies, and translating cardiac peptide biology into clinical biomarker applications.
Dr. Wright's engineered natriuretic peptide variant achieved a 6-fold half-life improvement and is now in Phase 1 clinical evaluation at three US medical centers.
A PEGylation strategy that worked in buffer failed in vivo due to rapid renal clearance of the conjugate. Dr. Wright now performs all half-life testing in conscious rat models before advancing to GLP toxicology studies.
Disclaimer: Content on peptavision.com is for educational and research purposes only. Not medical advice. Peptides for research use only. Consult a qualified healthcare professional.
Procurement & Research Inquiry
Connect with our peptide sciences team for research-grade peptides
